Zacks.com on MSN2d
CHMP Issues Positive Opinion for Label Expansion of BMY's OpdivoBMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by ...
Zacks Investment Research on MSN1d
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & MoreIt was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) perioperative treatment regimen has been recommended by the European Medicines Agency’s human medicines committee for adults with ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab ...
Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products ...
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
During a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune ...
EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...
Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...
CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug
CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback